Revance Therapeutics, Inc. (RVNC)

Revance Therapeutics Revenue

Revance Therapeutics had revenue of $236.65M in the twelve months ending March 31, 2024, with 54.59% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $51.94M with 13.46% year-over-year growth. In the year 2023, Revance Therapeutics had annual revenue of $234.04M with 76.55% growth.

• Revenue (ttm): $236.65M
• Revenue Growth: +54.59%
• P/S Ratio: 1.07
• Revenue / Employee: $396,390
• Employees: 597
• Market Cap: 252.76M USD

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	234.04M	101.48M	76.55%
Dec 31, 2022	132.57M	54.77M	70.40%
Dec 31, 2021	77.80M	62.47M	407.65%
Dec 31, 2020	15.33M	14.91M	3,610.65%
Dec 31, 2019	413.00K	-3.32M	-88.92%
Dec 31, 2018	3.73M	3.47M	1,323.28%
Dec 31, 2017	262.00K	-38.00K	-12.67%
Dec 31, 2016	300.00K	-	-
Dec 31, 2015	300.00K	-83.00K	-21.67%
Dec 31, 2014	383.00K	-234.00K	-37.93%
Dec 31, 2013	617.00K	-100.00K	-13.95%
Dec 31, 2012	717.00K	160.00K	28.73%
Dec 31, 2011	557.00K	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.